Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. (20th February 2022)

• Record Type: Journal Article
• Authors: Bramante, Carolyn T; Proper, Jennifer L; Boulware, David R; Karger, Amy B; Murray, Thomas; Rao, Via; Hagen, Aubrey; Tignanelli, Christopher J; Puskarich, Michael; Cohen, Ken; Liebovitz, David M; Klatt, Nichole R; Broedlow, Courtney; Hartman, Katrina M; Nicklas, Jacinda; Ibrahim, Sherehan; Zaman, Adnin; Saveraid, Hanna; Belani, Hrishikesh; Ingraham, Nicholas; Christensen, Grace; Siegel, Lianne; Sherwood, Nancy E; Fricton, Regina; Lee, Sam; Odde, David J; Buse, John B; Huling, Jared D
• Is Part Of: Open forum infectious diseases. Volume 9:Number 5(2022)
• Publication Date: 2022-02-20
• Subjects: SARS-CoV-2 -- symptoms -- vaccines -- viral load; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac066
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between vaccinated and unvaccinated adults enrolled in a randomized trial of outpatient coronavirus disease 2019 (COVID-19) treatment. Methods: Baseline data from the first 433 sequential participants enrolling into the COVID-OUT trial were analyzed. Adults aged 30–85 with a body mass index (BMI) ≥25 kg/m 2 were eligible within 3 days of a positive SARS-CoV-2 test and <7 days of symptoms. Log10 polymerase chain reaction viral loads were normalized to human RNase P by vaccination status, by time from vaccination, and by symptoms. Results: Two hundred seventy-four participants with known vaccination status contributed optional nasal swabs for viral load measurement: median age, 46 years; median (interquartile range) BMI 31.2 (27.4–36.4) kg/m 2 . Overall, 159 (58%) were women, and 217 (80%) were White. The mean relative log10 viral load for those vaccinated <6 months from the date of enrollment was 0.11 (95% CI, –0.48 to 0.71), which was significantly lower than the unvaccinated group ( P = .01). Those vaccinated ≥6 months before enrollment did not differ from the unvaccinated with respect to viral load (mean, 0.99; 95% CI, –0.41 to 2.40; P = .85). The vaccinated group had fewer moderate/severe symptoms of subjective fever, chills, myalgias, nausea, and diarrhea (all P < .05). Conclusions: These data suggest that vaccination within 6 months of infection is associated with a lower viral load, and vaccination was associated with a lower likelihood of having systemic symptoms.